- Tocilizumab for COVID-19 linked to increased risk of neutropenia.
- Convalescent plasma showed potential risks in specific subgroups.
- Importance of continued postmarket safety surveillance emphasized for COVID-19 treatments.
- Association between serious adverse events and FDA-authorized COVID-19 treatments evaluated.
- Specific subgroups, particularly hospitalized or immunocompromised patients, may face elevated risks with tocilizumab or convalescent plasma.
Source: Open Forum Infectious Diseases
